A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

Japan Approves Worlds First iPS Therapies for Parkinsons, Heart Failure Conditional approval granted for Sumitomo Pharmas ...

Japanese government experts endorsed on Thursday ground-breaking projects to manufacture regenerative medicine products to ...

Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

The earliest they are likely to become available is around summer, after drug pricing has been finalized. These products will be covered by the public health insurance system. The out-of-pocket burden ...

Tokyo-based K Pharma Inc. and Nikon Cell Innovation Co. on Tuesday signed a basic agreement on a new clinical trial project using induced pluripotent stem (iPS) cells to treat spinal cord injuries.

Induced pluripotent stem cells (iPS cells) can be created from any tissue in the human body and possess the ability to transform into a wide range of tissues. Kobe University MARUYAMA Tatsuo and his ...

A groundbreaking clinical trial is testing whether specially engineered stem cells can help the brain restore its own ...

Southwest Research Institute (SwRI) has demonstrated a new application for its cell-expansion bioreactor to advance tissue engineering and cell-based therapies for treatment of injuries and diseases.